Credits Available: 4.5 AMA PRA Category 1 Credit™ & 4.5 MOC points, 4.5 ACPE

Description: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries, with an age-adjusted incidence of 4.6 per 100,000 individuals per year. As small lymphocytic lymphoma (SLL) refers to the same malignant process with primary nodal involvement rather than blood, these are generally managed as a single condition (CLL/SLL). The selection of therapies for patients with relapsed/refractory CLL/SLL requires consideration of several factors including previous therapies, disease characteristics, and patient-specific factors such as co-morbidities and concurrent medications. Given the recency of new research into these targeted treatments and new approvals, clinicians lack background knowledge of the most current evidence and guideline recommendations in the treatment of CLL/SLL. Even within national guidelines, specific recommendations for initial treatment choice and sequencing are not directed. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Hematology, Hematology/Oncology, Oncology

Reem Karmali

Northwestern University, Feinberg School of Medicine

Dr. Karmali’s overarching goal is to improve outcomes for patients with lymphoma though practice and research. Her clinical research focuses on identifying novel targets for drug design and development including cellular therapies. Her translational research explores on the role of metabolic dysregulation in lymphomagenesis and resistance to therapy. She has published widely, authoring more than 100 peer-reviewed journal articles.